Immunometabolism is a rapidly growing field which has emerged from recent findings that cellular metabolism has a direct role in influencing immune function and disease, and that switches between alternative metabolic pathways allow immune cells to adapt to their environment by changing phenotype, responsiveness and longevity.

Istesso’s pipeline consists of drugs that reprogramme metabolism in target immune cells, thereby offering novel treatments for autoimmune conditions such as rheumatoid arthritis, multiple sclerosis and ulcerative colitis, as well as cancer.

Phase I
Phase II
Phase III
MBS2320 Rheumatoid arthritis
Phase II 50%
MBS2320 RA-2
Phase I 100%
MBS2320 Autoimmune 2
Phase I 100%
MBS2612 Autoimmune, Neuroprotection/fibrosis
Pre-clinical 25%
IST003 Autoimmune, Neuroprotection/fibrosis
Discovery 75%
IST004 Neuroprotection/autoimmunity
Discovery 50%
IST005 Autoimmunity/inflammation
Discovery 25%